Our goal was to create a patent-free, low-cost COVID-19 vaccine that could be produced locally in low- and middle-income countries. This is about saving lives, not profits.

Analyse

Bottazzi and her team at Texas Children’s Hospital and Baylor College of Medicine developed **Corbevax** using traditional protein-subunit technology, explicitly rejecting patent protections to enable low-cost production. The vaccine was licensed to **Biological E. Limited (India)** and other manufacturers in **low- and middle-income countries (LMICs)**, with doses priced at **$1.50–$2**—far below mRNA alternatives. Bottazzi has consistently framed the project as a **humanitarian effort**, emphasizing local production to avoid supply-chain dependencies seen with patented vaccines. Independent reports (e.g., *Nature*, *STAT News*) confirm these goals and outcomes.

Achtergrond

Corbevax received **emergency use authorization in India (Dec 2021)** and later in **Botswana, Indonesia, and other LMICs**, though it faced delays in WHO EUL approval. The vaccine’s **open IP model** contrasts with Pfizer/Moderna’s patented mRNA vaccines, which faced criticism for inequitable distribution. Bottazzi’s work aligns with broader **global health equity movements**, such as the WHO’s COVID-19 Technology Access Pool (C-TAP).

Samenvatting verdict

Maria Elena Bottazzi accurately described Corbevax as a patent-free, low-cost COVID-19 vaccine designed for equitable global access, prioritizing public health over profits.

Geraadpleegde bronnen